drugset / Trial / NCT00310674

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

NCT00310674

Phase 3 Completed 150 enrolled Novartis Novartis Vaccines · collab
Non-randomizedSingle-groupOpen-labelPrevention

Summary

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 months of age

Timeline

Start
2004-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Menjugate Vaccine